Novo Nordisk Stock Skids As Report Finds ‘Objectionable’ Conditions At A Key Wegovy Plant

Novo Nordisk (NVO) stock skidded Monday on reports a Food and Drug Administration inspection turned up “objectionable conditions” at a facility charged with making diabetes and weight-loss drugs.

X

According to Reuters — which cited a Market Wire News report — the FDA inspectors filed a Form 483 following their inspection of Novo Nordisk’s Clayton, N.C., manufacturing plant. That form lists any conditions the inspector found that could violate the Food and Drug Cosmetic Act and…